CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 DEFINE AND CONFIRM STUDIES

被引：1
|
作者：
Bar-Or, A. [1 ]
Fox, R. J. [2 ]
Gold, R. [3 ]
Miller, D. H. [4 ]
Arnold, D. L. [1 ,5 ]
O'Gorman, J. [6 ]
Yang, M. [6 ]
Sheikh, S., I [6 ]
Viglietta, V. [6 ]
Dawson, K. T. [6 ]
Hutchinson, M. [7 ]
机构：
[1] Montreal Neurol Hosp & Inst, Montreal, PQ, Canada
[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[3] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[4] UCL, Inst Neurol, London, England
[5] NeuroRx Res, Montreal, PQ, Canada
[6] Biogen Idec Inc, Weston, MA USA
[7] St Vincents Univ Hosp, Dublin 4, Ireland
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.481
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A102 / A102
页数：1
相关论文
共 50 条
  • [31] Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
    Bar-Or, Amit
    Gold, Ralf
    Kappos, Ludwig
    Arnold, Douglas
    Giovannoni, Gavin
    Selmaj, Krzysztof
    O'Gorman, John
    Stephan, Monica
    Dawson, Katherine
    [J]. NEUROLOGY, 2012, 78
  • [32] Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis
    Ruggieri, Serena
    Tortorella, Carla
    Gasperini, Claudio
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 229 - 239
  • [33] Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis: results from the phase 3 CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
    Havrdova, E.
    Phillips, J. T.
    Fox, R. J.
    Miller, D.
    Kita, M.
    Hutchinson, M.
    Raghupathi, K.
    Yuan, H.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    [J]. JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S105
  • [34] BG-12 (Dimethyl Fumarate) Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies
    Havrdova, Eva
    Gold, Ralf
    Fox, Robert
    Kappos, Ludwig
    Phillips, J. Theodore
    Zhang, Annie
    Kurukulasuriya, Nuwan
    Sheikh, Sarah
    Viglietta, Vissia
    Dawson, Katherine
    Giovannoni, Gavin
    [J]. NEUROLOGY, 2013, 80
  • [35] Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis
    Kappos, Ludwig
    Giovannoni, Gavin
    Gold, Ralf
    Fox, Robert
    Phillips, J. Theodore
    Hotermans, Christophe
    Zhang, Annie
    Viglietta, Vissia
    Miller, David
    [J]. NEUROLOGY, 2013, 80
  • [36] Safety and Tolerability of BG-12 (Dimethyl Fumarate) in Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of Phase 2 and 3 Placebo-Controlled Studies
    Phillips, J. Theodore
    Fox, Robert
    Gold, Ralf
    Havrdova, Eva
    Kappos, Ludwig
    Raghupathi, Kartik
    Yuan, Huixing
    Viglietta, Vissia
    Sheikh, Sarah
    Dawson, Katherine
    Novas, Mark
    Sweetser, Marianne
    Selmaj, Krzysztof
    [J]. NEUROLOGY, 2013, 80
  • [37] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
    Michael Hutchinson
    Robert J. Fox
    David H. Miller
    J. Theodore Phillips
    Mariko Kita
    Eva Havrdova
    John O’Gorman
    Ray Zhang
    Mark Novas
    Vissia Viglietta
    Katherine T. Dawson
    [J]. Journal of Neurology, 2013, 260 : 2286 - 2296
  • [38] Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses From the CONFIRM Study
    Phillips, J. Theodore
    Fox, Robert
    Miller, David
    Kita, Mariko
    Hutchinson, Michael
    Havrdova, Eva
    Raghupathi, Kartik
    Yuan, Huixing
    Novas, Mark
    Viglietta, Vissia
    Dawson, Katherine
    [J]. NEUROLOGY, 2012, 78
  • [39] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study
    Amit Bar-Or
    Ralf Gold
    Ludwig Kappos
    Douglas L. Arnold
    Gavin Giovannoni
    Krzysztof Selmaj
    John O’Gorman
    Monica Stephan
    Katherine T. Dawson
    [J]. Journal of Neurology, 2013, 260 : 2297 - 2305
  • [40] Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis
    Selmaj, K.
    Gold, R.
    Kappos, L.
    Bar-Or, A.
    Arnold, D.
    Giovannoni, G.
    Sweetser, M.
    Novas, M.
    Raghupathi, K.
    Dawson, K.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S451 - S451
12345